Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma: a Double Blind Prospective Randomzed Study
Who is this study for? Patients with Melanosis
Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• SIGNED WRITTEN CONSENT 1) Melasma clinically diagnosed
Locations
Other Locations
France
CHU de Nice
Nice
Time Frame
Start Date: 2021-11-30
Completion Date: 2022-12-15
Participants
Target number of participants: 40
Treatments
Experimental: New traitement
Thiamidol, retinoid, topical steroid preparation
Other: Kligman's trio
Application once a day for 12 weeks
Authors
Passeron Thierry
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de Nice